An integrated discovery-to-commercialization provider spanning research reagents, custom synthesis, process development, analytical and quality control, CMC, APIs, drug product and commercial manufacturing.
Core modalities
Pre-generated AI ranking
Score model: gpt-5.4-miniGenerated: Aug 24, 2026, 7:24 PM PDTRead-only snapshot
Wave has a diversified RNA pipeline and multiple chemistry modalities that fit CDMO 2 oligonucleotide and analytical capabilities.
Recommended services
Public evidence
Official site lists RNA editing, RNAi, splicing and antisense clinical programs. Source
Arrowhead has a large RNAi pipeline and marketed product, creating strong technical fit but potentially entrenched late-stage suppliers.
Recommended services
Public evidence
Official pipeline includes marketed and Phase 3 RNAi medicines. Source
Dyne has late-stage oligonucleotide conjugates and follow-on programs that align with CDMO 2 process, analytical and manufacturing services.
Recommended services
Public evidence
Official pipeline includes regulatory-stage and Phase 3 conjugated oligonucleotide programs. Source
PepGen peptide-oligonucleotide conjugates directly overlap with CDMO 2 peptide, oligonucleotide and conjugation capabilities.
Recommended services
Public evidence
Official pipeline centers on a Phase 2 peptide-conjugated oligonucleotide. Source
Sutro next-generation ADC programs align with CDMO 2 ADC, linker, payload, conjugation and manufacturing services.
Recommended services
Public evidence
Official pipeline lists multiple single- and dual-payload ADC programs. Source
Nurix combines targeted degraders with degrader-antibody conjugates, matching CDMO 2 complex chemistry and conjugation capabilities.
Recommended services
Public evidence
Official pipeline identifies degrader and conjugate programs across clinical stages. Source
IDEAYA operates both small-molecule and ADC pipelines across several clinical stages, matching CDMO 2 breadth from discovery through manufacturing.
Recommended services
Public evidence
Official pipeline shows nine clinical-stage programs across small molecules and ADCs. Source
Immunome has one clinical and multiple preclinical ADC programs, creating clear demand categories for ADC development and manufacturing support.
Recommended services
Public evidence
Official pipeline lists clinical and preclinical ADC candidates. Source
Revolution Medicines has complex clinical RAS inhibitors with technical fit for process and manufacturing services, but likely established suppliers.
Recommended services
Public evidence
Official pipeline lists multiple late- and early-clinical oral RAS inhibitors. Source
Kura has relevant small-molecule manufacturing needs, though its commercial stage suggests a higher switching barrier.
Recommended services
Public evidence
Official pipeline includes an approved small molecule and several clinical programs. Source
Kymera targeted degraders align with CDMO 2 complex small-molecule and CMC capabilities.
Recommended services
Public evidence
Official site describes a multi-program clinical degrader pipeline. Source
Monte Rosa molecular glue degraders require complex small-molecule synthesis and CMC support that fit CDMO 2 capabilities.
Recommended services
Public evidence
Official pipeline lists clinical and preclinical molecular glue degraders. Source
Treeline spans inhibitors, degraders and ADCs, closely matching CDMO 2 broad discovery and CDMO platform.
Recommended services
Public evidence
Official site describes clinical small-molecule/degrader programs and an ADC capability. Source
Relay precision small molecules fit CDMO 2 discovery chemistry, custom synthesis and process capabilities.
Recommended services
Public evidence
Official pipeline lists clinical and early-stage precision small molecules. Source
Septerna is moving several oral small-molecule programs toward and through clinical development, fitting integrated CRO/CDMO support.
Recommended services
Public evidence
Official pipeline lists discovery, IND-enabling and Phase 1 GPCR programs. Source
Frontier has multiple covalent small-molecule programs whose discovery and scale-up needs match CDMO 2 services.
Recommended services
Public evidence
Official site describes a clinical and preclinical covalent small-molecule pipeline. Source
Nimbus has a renewable clinical and preclinical small-molecule portfolio fitting CDMO 2 chemistry and development services.
Recommended services
Public evidence
Official pipeline covers small molecules in oncology, immunology and metabolism. Source
Odyssey has a growing set of small-molecule immunology assets across early and clinical stages.
Recommended services
Public evidence
Official pipeline lists multiple small-molecule programs from discovery to Phase 2. Source
Arvinas programs fit CDMO 2 degrader and manufacturing capabilities, although commercialization maturity may lower near-term vendor openness.
Recommended services
Public evidence
Official pipeline includes approved and clinical PROTAC programs. Source
Neumora has several small-molecule assets at transition points where integrated chemistry and CMC support may add capacity.
Recommended services
Public evidence
Official pipeline lists preclinical through Phase 2 small molecules. Source
